Mustang Bio, Inc. (MBIO) experienced a significant pre-market surge of over 207 percent on the Nasdaq. This jump followed the announcement of promising efficacy and safety data from their ongoing Phase 1/2 clinical trial of MB-106. MB-106 is a CD20-targeted, autologous CAR T-cell therapy for patients with Waldenstrom macroglobulinemia (WM), a rare type of blood cancer.
The company acknowledged that advancing the MB-106 program for other hematologic malignancies will require substantial additional funding or a strategic partnership.
MB-106 is being co-developed with Fred Hutch Cancer Center to treat relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL).
The encouraging data from the MB-106 trial was presented during a poster session at the European Hematology Association’s 2024 Hybrid Congress. All ten patients in the trial had previously been treated with Bruton's tyrosine kinase inhibitors (BTKi), but their diseases progressed despite these treatments.
Results showed that 90% of the patients responded to MB-106 treatment. This included 3 complete responses, 2 very good partial responses, and 4 partial responses. Additionally, 1 patient achieved stable disease.
For more health news, visit rttnews.com.
